|Articles|September 1, 2002

Take a close look at property taxes for major savings

Unknown deductibles, correction of human error, and value reassessmentcan all add upNow might be a good time for every urologist to take a look at the often-neglectedproperty or real estate tax on all the property owned by your practice.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

Pearls & Perspectives: Understanding the Long-Term Health Effects of Military Exposures, With Shane Kronstedt, MD

ByAmy M. Pearlman, MD,Larry Lipshultz, MD,Shane M. Kronstedt, MD

July 22nd 2026

Experts discuss the challenge of detecting CIS in bladder cancer

ByArpeet Shah, MD,Prithvi Murthy, MD,Kenneth Beck, MD

July 21st 2026

Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC

ByHannah Clarke

July 21st 2026

Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC

ByTyler Garman, MD

July 21st 2026

First-in-human bladder transplant demonstrates sustained function at 6 months

ByHannah Clarke

July 20th 2026

Latest CME

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Video

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Take a close look at property taxes for major savings

Related Content

Pearls & Perspectives: Understanding the Long-Term Health Effects of Military Exposures, With Shane Kronstedt, MD

Experts discuss the challenge of detecting CIS in bladder cancer

Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC

Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC

First-in-human bladder transplant demonstrates sustained function at 6 months

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Radioligand Therapy 101: The Science Behind the Strategy

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Trending on Urology Times

Experts discuss the challenge of detecting CIS in bladder cancer

Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC

Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC

Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation

Department of Defense announces annual testosterone deficiency screening for service members